Skip to Content

The MD Anderson Symptom Inventory Head and Neck Cancer Module (MDASI-HN)

ORDER ASSESSMENT TOOLS

  

MD Anderson Symptom Inventory (MDASI) modules augment the 19 core MDASI symptom and interference items with additional items identified as unique to a particular patient population. MDASI modules may be disease-specific, disease-site-specific, or treatment-specific.

The MDASI-HN is a site-specific module. Along with the core MDASI’s 13 symptom items and 6 interference items, the MDASI-HN also assesses 9 symptom items relevant to head and neck cancer: mucus in the mouth and throat, difficulty swallowing/chewing, choking/coughing, difficulty with voice/speech, skin pain/burning/rash, constipation, problems with tasting food, mouth/throat sores, and problems with teeth or gums.

MDASI-HN Features

  • Purpose: To assess the severity of multiple head and neck cancer-related symptoms and the impact of these symptoms on daily functioning
  • Population: Patients with symptoms caused by head and neck cancer and its treatment
  • Assessment areas: Severity of multiple symptoms and the impact of symptoms on daily functioning during the last 24 hours
  • Method: Self-report; paper-and-pencil form or tablet PC (self-administered or via interview), or telephone-based interactive voice response (IVR) system
  • Time required: Five minutes
  • Scoring: Please see the MDASI User's Guide
  • Reliability: Cronbach alpha reliability ranges from 0.72 to 0.92

MDASI-HN Language Versions

The MDASI-HN is available in the languages shown below. Click on a linked language to view a sample in PDF format.

Psychometrically and Linguistically ValidatedLinguistically Validated
English

Chinese (Simplified)
Danish
Dutch
French
German
Greek
Italian
Spanish
Turkish

  
Future Validation Studies: We would like to collaborate with other investigators to develop and validate new language versions of the MDASI-HN. Contact us for more information. NOTE: The MDASI-HN may not be modified or translated into another language without express written consent (see Notice of Copyright below).

To Order the MDASI-HN

To use the MDASI-HN in a publication or clinical or research trial, you must obtain permission by filling out our order form and you must comply with the copyright. Fees may apply:

Type of UseFirst Language Version (Per Project)Additional Language Versions (Per Project)
Non-funded academic researchNo chargeNo charge
Individual clinical practiceNo chargeNo charge
Funded academic research$300$150
Commercial research$2,000$1,200

 
The MDASI-HN will be e-mailed to you as a PDF file within 7 to 10 business days. If your request is urgent or the language version you seek is not shown, contact us to make special arrangements:

Department of Symptom Research
Attn: Assessment Tools
The University of Texas MD Anderson Cancer Center
1515 Holcombe Boulevard, Unit 1450
Houston, Texas 77030
symptomresearch@mdanderson.org  

If applicable, an invoice will be e-mailed to you. Reference the invoice number on your payment and include on the memo line, "MD Anderson Assessment Tool Distribution."

Notice of Copyright

The M. D. Anderson Symptom Inventory (MDASI) copyright is held by The University of Texas MD Anderson Cancer Center and administered by the MDASI's developer, Charles S. Cleeland, PhD. The copyright applies to the MDASI, its modules, and all its derivatives in any language.

The MDASI-HN may not be used or reproduced without permission from Charles S. Cleeland, PhD, or his designee. Fees for use may apply (see above).

The MDASI and its modules may not be modified or translated into another language without the express written consent of the copyright holder. Failure to comply may result in legal action. Contact us via e-mail at symptomresearch@mdanderson.org or at the address shown above to obtain permission to alter or translate the instrument.

Selected References

Validation

Rosenthal DI, Mendoza TR, Chambers MS, Asper JA, Gning I, Kies MS, Weber RS, Lewin JS, Garden AS, Ang KK, Wang S, Cleeland CS. Measuring head and neck cancer symptom burden: The development and validation of the M. D. Anderson Symptom Inventory, head and neck module. Head Neck 29(10): 923-931, 2007.

Gunn GB, Koukourakis MI, Mendoza TR, Cleeland CS, Rosenthal DI. Linguistic validation of the Greek M. D. Anderson Symptom Inventory -- Head and Neck Module. Forum of Clinical Oncology 3(1): 17-19, 2012.

Cleeland CS, Mendoza TR, Wang XS, Chou C, Harle M, Morrissey M, & Engstrom MC. Assessing Symptom Distress in Cancer: The M. D. Anderson Symptom Inventory. Cancer 89:1634-1646, 2000.

Clinical Application

Rosenthal DI, Mendoza TR, Chambers MS, Burkett VS, Garden AS, Hessell AC, Lewin JS, Ang KK, Kies MS, Gning I, Wang XS, Cleeland CS. The M. D. Anderson symptom inventory-head and neck module, a patient-reported outcome instrument, accurately predicts the severity of radiation-induced mucositis. Int J Radiat Oncol Biol Phys 72(5): 1355-1361, 2008.

Gunn GB, Chronowski GM, Garden AS, Frank SJ, Morrison WH, Beadle BM, Lewis CM, Mendoza TR, Cleeland CS, Rosenthal DI. Symptom-free cure following unilateral radiation therapy for tonsil cancer: a PRO benchmark [abstract]. American Society for Radiation Oncology 54th Annual Meeting, Boston MA, Oct 28-31, 2012, 2012; 2012-A-511-ASTRO.

Rosenthal DI, Gunn GB, Garden AS, Lu C, Mendoza TR, Morrison WH, Frank SJ, Beadle BM, Phan J, Fuller CD, Hanna EY, Ang KK, Cleeland CS. Pattern of symptoms in head and neck cancer (HNC) survivors treated with radiation therapy (RT): association with systemic therapy [abstract]. American Society of Clinical Oncology 48th Annual Meeting, Chicago IL, Jun 1-5, 2012. J Clin Oncol 30(Suppl 1), 2012; 5589.

Gunn GB, Fuller CD, Garden AS, Frank SJ, Morrison WH, Beadle BM, Phan J, Mendoza TR, Hanna EY, Ang KK, Cleeland CS, Rosenthal DI. Patient-reported symptoms following IMRT alone for oropharynx cancer: A survivorship study [abstract]. American Society of Clinical Oncology 48th Annual Meeting, Chicago IL, Jun 1-5, 2012. J Clin Oncol 30(Suppl 1), 6/2012; 5561.

Rosenthal DI, Gunn GB, Mendoza TR, Garden AS, Beadle BM, Morrison WH, Wang XS, Frank SJ, Weber RS, Ang KK, Cleeland CS. Long-term symptom burden after radiation treatment for oropharynx cancer: A comparison of 3D and IMRT techniques [abstract]. American Society of Clinical Oncology 47th Annual Meeting, Chicago IL, Jun 3-7, 2011. J Clin Oncol 29(15 Suppl), 2011; 5539.

Gunn GB, Mendoza TR, Garden AS, Wang XS, Morrison WH, Frank SJ, Hanna EY, Lu C, Beadle BM, Ang KK, Cleeland CS, Rosenthal DI. Patient-reported fatigue in head and neck cancer survivors [abstract]. American Society of Clinical Oncology 47th Annual Meeting, Chicago IL, Jun 3-7, 2011. J Clin Oncol 29(15 Suppl), 2011; 5523.

Rosenthal DI, Mendoza TR, Gunn GB, Wang XS, Hessell AC, Garden AS, Morrison WH, Cleeland CS. The persistence of symptom burden after radiation treatment for head and neck cancer [abstract]. American Society of Clinical Oncology 2010 Annual Meeting, Chicago IL, Jun 4-8, 2010. J Clin Oncol 28(15 Suppl): 439s, 2010; 5573.

Gunn GB, Mendoza TR, Wang XS, Garden AS, Lewin JS, Morrison WH, Frank SJ, Chambers MS, Cleeland CS, Rosenthal DI. The relationship of presenting symptom burden and survival in patients with head and neck cancer (HNC) [abstract]. American Society of Clinical Oncology 2010 Annual Meeting, Chicago IL, Jun 4-8, 2010. J Clin Oncol 28(15 Suppl): 446s, 2010; 5600.

Badr H, Rosenthal DI, Milbury K, Garden AS, Frank SJ, Gunn GB, Cleeland CS, Gritz ER. Do the treatment outcome priorities of head and neck cancer patients change after undergoing radiation treatment? [abstract]. American Society of Clinical Oncology 2010 Annual Meeting, Chicago IL, Jun 4-8, 2010. J Clin Oncol 28(15 Suppl): 445s, 2010; 5599.

Rosenthal DI, Mendoza T, Cleeland C. Identifying head and neck patients at risk for high symptom burden during treatment [abstract]. American Society of Clinical Oncology 2009 Annual Meeting, Orlando FL, May 29 - Jun 2, 2009. J Clin Oncol 27(15 Suppl), 2009; 6066.

Methodology

Mendoza TR, Gunn GB, Fuller CD, Wang XS, Rosenthal DI, Cleeland CS. The utility of using area under the curve to analyze symptom burden during radiation/chemoradiation for head & neck cancer [abstract]. American Society of Clinical Oncology 47th Annual Meeting, Chicago IL, Jun 3-7, 2011. J Clin Oncol 29(15 Suppl), 6/2011; 5525.

Shi Q, Rosenthal DI, Mendoza T, Cleeland CS. Using group-based trajectory modeling to examine heterogeneity of cancer-related symptoms [abstract]. International Society for Quality of Life Research 17th Annual Conference, London, England, Oct 27-30, 2010. Qual Life Res 19(Suppl 1): 51, 2010; 1393.

Mendoza T, Rosenthal D, Wang X, Mobley G, Cleeland C. Measuring the symptom burden of head and neck cancer patients undergoing concurrent chemotherapy and radiation therapy using area under the curve [abstract]. American Society of Clinical Oncology 2009 Annual Meeting, Orlando FL, May 29 - Jun 2, 2009. J Clin Oncol 27(15 Suppl), 5/2009; 6067.

Related News

Symptom Research hosts national colloquium on developing strategies for reducing cancer treatment-related toxicities and symptoms. Read more...

 Cancer Symptom Science

Announcing the publication of Cancer Symptom Science, an interdisciplinary, first-of-its-kind compilation of research on the mechanisms underlying the expression of cancer-related symptoms. Read more...

Old Drugs, New Possibilities (Conquest, Fall 2008)

Symptom Research Awarded NIH P01 Grant (Division of Internal Medicine Newsletter, Summer 2008)

Symptom Research and Psychometrics (Network, Summer 2008)


© 2014 The University of Texas MD Anderson Cancer Center